Can we predict outcomes in atrial fibrillation?

Clinical Cardiology

Volumn 35, Issue SUPPL. 1, 2012, Pages 10-14

  Desai, Nihar R ^a   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CANDESARTAN; CLOPIDOGREL; DRONEDARONE; FIBRINOGEN RECEPTOR ANTAGONIST; IRBESARTAN; STREPTOKINASE; VALSARTAN; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BRADYCARDIA; CARDIOVERSION; COMORBIDITY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; STROKE; SURVIVAL RATE; TACHYCARDIA;

ACUTE CORONARY SYNDROME; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HEART FAILURE; HOSPITALIZATION; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 84855922902     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20989     Document Type: Review

References (36)

1. Wattigney WA, Mensah GA, Croft JB., Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 Through 1999. Circulation. 2003; 108: 711-716. (Pubitemid 36999256)
2. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011; 4: 313-320.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998; 98: 946-952. (Pubitemid 28446646)
4. Stewart S., A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med. 2002; 113: 359-364. (Pubitemid 35223606)
5. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011; 305: 2080-2087.
6. Go AS., The ACTIVE Pursuit of Stroke Prevention in Patients with Atrial Fibrillation. N Engl J Med. 2009; 360: 2127-2129.
7. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.
8. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360: 668-378.
9. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825-1833.
10. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347: 1834-1840. (Pubitemid 35417774)
11. Van Gelder IC, Groenveld HF, Crijns HJGM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362: 1363-1373.
12. Redfield MM., Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc. 2000; 75: 790-795. (Pubitemid 30640636)
13. Kieny JR., Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13: 1290-1295.
14. Ohno M, Cheng CP, Little WC., Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994; 89: 2241-2250. (Pubitemid 24142804)
15. Fujino T, Yamashita T, Suzuki S, et al. Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J. 2007; 71: 936-940. (Pubitemid 46833934)
16. Wang TJ., Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107: 2920-2925. (Pubitemid 36736633)
17. Dries DL., Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am CollCardiol. 1998; 32: 695-703. (Pubitemid 28435256)
18. Olsson LG., Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am CollCardiol. 2006; 47: 1997-2004.
19. Carson PE., The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87: VI102-VI110. (Pubitemid 23164229)
20. Brown AM, Sease KL, Robey JL, et al. The risk for acute coronary syndrome associated with atrial fibrillation among ED patients with chest pain syndromes. Am J Emerg Med. 2007; 25: 523-528. (Pubitemid 46824166)
21. ACTIVE Writing Group of the ACTIVE Investigators;, Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
22. Schmitt J., Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. EurHeart J. 2009; 30: 1038-1045.
23. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am CollCardiol. 1997; 30: 406-413. (Pubitemid 27339320)
24. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000; 140: 878-885.
25. Pizzetti F, Turazza FM, Franzosi MG, et al. GISSI-3 Investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527-532. (Pubitemid 32999863)
26. Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 1990; 119: 996-1001. (Pubitemid 20155273)
27. Lehto M, Snapinn S, Dickstein K, et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. EurHeart J. 2005; 26: 350-356. (Pubitemid 40287380)
28. Kinjo K, Sato H, Ohnishi Y, et al. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol. 2003; 92: 1150-1154. (Pubitemid 37377822)
29. Kober L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006; 8: 591-598. (Pubitemid 44604352)
30. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011; 123: 2094-2100.
31. Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome. Am J Cardiol. 1998; 82: 1205-1209. (Pubitemid 28541275)
32. Kuga K, Yamaguchi I, Sugishita Y, et al. Assessment by autonomic blockade of age-related changes of the sinus node function and autonomic regulation in sick sinus syndrome. Am J Cardiol. 1988; 61: 361-366.
33. Flaker G, Greenspon A, Tardiff B, et al. Death in patients with permanent pacemakers for sick sinus syndrome. Am Heart J. 2003; 146: 887-893. (Pubitemid 37378580)
34. Klein G, Lissel C, Fuchs AC, et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. Europace. 2006; 8: 618-624. (Pubitemid 44295759)
35. Sharma AD, Klein GJ, Guiraudon GM, et al. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circulation. 1985; 72: 161-169. (Pubitemid 15069589)
36. Gulamhusein S, Ko P, Carruthers SG, et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation. 1982; 65: 348- 354.